These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 26836778)

  • 1. Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymerase.
    Talamas FX; Abbot SC; Anand S; Brameld KA; Carter DS; Chen J; Davis D; de Vicente J; Fung AD; Gong L; Harris SF; Inbar P; Labadie SS; Lee EK; Lemoine R; Le Pogam S; Leveque V; Li J; McIntosh J; Nájera I; Park J; Railkar A; Rajyaguru S; Sangi M; Schoenfeld RC; Staben LR; Tan Y; Taygerly JP; Villaseñor AG; Weller PE
    J Med Chem; 2014 Mar; 57(5):1914-31. PubMed ID: 24195700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.
    Ito J; Suda G; Yamamoto Y; Nagasaka A; Furuya K; Kumagai K; Kikuchi H; Miyagishima T; Kobayashi T; Kimura M; Yamasaki K; Umemura M; Izumi T; Tsunematsu S; Sato F; Tsukuda Y; Terashita K; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    Hepatol Res; 2016 Dec; 46(13):1294-1303. PubMed ID: 26896756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data.
    Chen ZW; Li H; Ren H; Hu P
    Sci Rep; 2016 Feb; 6():20310. PubMed ID: 26842909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation.
    Han D; Wang H; Wujieti B; Zhang B; Cui W; Chen BZ
    Comput Struct Biotechnol J; 2021; 19():2761-2774. PubMed ID: 34093991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the binding mechanisms of diaminopimelic acid analogs to meso-diaminopimelate dehydrogenase by molecular modeling.
    Wang H; Kellogg GE; Xu P; Zhang Y
    J Mol Graph Model; 2018 Aug; 83():100-111. PubMed ID: 29885593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current therapy for chronic hepatitis C: The role of direct-acting antivirals.
    Li G; De Clercq E
    Antiviral Res; 2017 Jun; 142():83-122. PubMed ID: 28238877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors.
    Zhao C; Wang Y; Ma S
    Eur J Med Chem; 2015 Sep; 102():188-214. PubMed ID: 26276434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase.
    Tomei L; Altamura S; Paonessa G; De Francesco R; Migliaccio G
    Antivir Chem Chemother; 2005; 16(4):225-45. PubMed ID: 16130521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Cummings MD; Lin TI; Hu L; Tahri A; McGowan D; Amssoms K; Last S; Devogelaere B; Rouan MC; Vijgen L; Berke JM; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Fanning G; Nyanguile O; Simmen K; Van Remoortere P; Raboisson P; Vendeville S
    J Med Chem; 2014 Mar; 57(5):1880-92. PubMed ID: 24144360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study.
    Jiao P; Xue W; Shen Y; Jin N; Liu H
    Mol Biosyst; 2014 Apr; 10(4):767-77. PubMed ID: 24452008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
    Xue W; Jiao P; Liu H; Yao X
    Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.
    Devogelaere B; Berke JM; Vijgen L; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Nyanguile O; Tahri A; Amssoms K; Lenz O; Cummings MD; Clayton RF; Vendeville S; Raboisson P; Simmen KA; Fanning GC; Lin TI
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4676-84. PubMed ID: 22710121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational study on the drug resistance mechanism of HCV NS5B RNA-dependent RNA polymerase mutants V494I, V494A, M426A, and M423T to Filibuvir.
    Wang H; Guo C; Chen BZ; Ji M
    Antiviral Res; 2015 Jan; 113():79-92. PubMed ID: 25449363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling study on the drug resistance mechanism of NS5B polymerase to TMC647055.
    Wang H; Cui W; Guo C; Chen BZ; Ji M
    Biochem Cell Biol; 2016 Apr; 94(2):147-58. PubMed ID: 26836778
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.